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SUMMARY.-The effect of cysteine on the immunosuppressive activity of three
alkylating agents was tested. Cysteine strongly inhibited the ability of cyclo-
phosphamide and nitrogen mustard to depress the direct plaque-forming cell
response of mice to sheep red cells. In contrast, the activity of busulphan was
usually potentiated by administration of cysteine. This throws doubt on the
hypothesis that busulphan exerts its cytotoxic effects byalkylating thiol groups.
THIS communication is part of a study of the immunosuppressive activity of
the anti-tumour agent busulphan. There are two peculiarities in the behaviour
of the drug which render this activity worth investigating. First, its haemato-
logical and histological effects are predominantly upon the erythroid, platelet and
myeloidsystems, its observable effects onlymphoid organs andcirculatinglympho-
cytes being trivial except at supralethal doses (Elson, Galton, and Till, 1958;
Sternberg, Phillips and Scholler, 1958). Thus, the very system most intimately
connected with an immune response is apparently spared. Second, busulphan,
though an alkylating agent, is very much more active when administered before
antigen than afterwards. This contrasts with most other immunosuppressive
alkylating agents, which generally act best when administered after the antigen
(Berenbaum, 1967).
Cysteine is one of a group of chemicals which protect against the toxic effects
of radiation and so-called
" radiomimetic
" agents (Connors, 1966). It has
been shown that the immunosuppressive activity as well as the toxicity of one
such agent, nitrogen mustard, is reduced by the administration of' cysteine
(Berenbaum, 1966). It seemed appropriate to extend thisstudy to busulphan as
it is known to react with thiol groups in vivo (Roberts and Warwick, 1959) and
because this latter reaction may be ofimportance in its mechanism of action (see
discussion).
For comparative purposes, nitrogen mustard and cyclophosphamide were also
studied, because the toxicity of both is known to be reduced by eysteine (Brandt
and Griffin, 1951; Connors, 1966; Brinckner, 1964).
MATERIALS AND METHODS
Animals.-BALB/c female mice were used, weighing 14-20 g. at the start of
theexperiment.
DrUg&-(All materials were diluted so that the required amount was contained
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(1) Cyclophosphamide (pure substance, batch 6066, Ward, Blenkinsop and
Co. Ltd., London) was dissolved in salineimmediately before use; the solution was
given subcutaneously.
(2) Busulphan (Burroughs Wellcome and Co., Batch AN 31911) was adminis-
tered as a suspension in dehydrated arachis oil (see Berenbaum, Timmis and
Brown, 1967, for details). The dose used in these experiments, unless otherwise
stated, was 90mg./kg. This was in theregion of anLDO-10 over theexperimental
period.
(3) Nitrogen mustard (mustine hydrochloride B.P.) was dissolved in saline
and injected subcutaneously.
(4) L-Cysteine hydrochloride (Hopkins and Williams Ltd. Batch 42576
BO 1258 Laboratory Reagent) was dissolved in sodium hydroxide so that the
final solution had a pH of 7-2-7-4 (I g. ofcysteine was dissolved in 10 ml. of 0-63N
NaOH). Injections were intraperitoneal. One g./kg. was given at the time of
drug injection or just before, followed by injections of 0.5g./kg. every 2 hours for
up to 8 hours. Larger or more frequent injections were prohibitively toxic.
The particular regimen used in each experiment is given in the legend to the
appropriate figure. Groups not receiving cysteine received an equivalent volume
of saline.
Storage.-Busulphan suspensions were kept at -70' C. At this temperature
and in the absence of water, it is unlikely that any significant chemical change
wouldhave occurred overtheexperimentalperiod. Solutions ofnitrogenmustard,
cyclophosphamide and eysteine were used shortly after preparation and were not
stored.
Haemoly-gin response to 8heep red cells.-0-2 ml. of a 10% suspension ofwashed
red cells (Wellcome sheep blood, defibrinated, formolized) was injected intra-
venously. Spleens were removed 4 days later and the number of direct plaque-
forming cells (PFC) per spleen was assayed (Jerne and Nordin, 1963; Jerne,
Nordin and Henry, 1963). Throughout this paper the time at which antigen was
injected in anexperiment isdesignated 0hours;days or hours afterthis arereferred
to as positive, days or hours before this as negative.
Presentation of results.-The response is expressed as plaque-forming cells per
spleen (PFC/spleen). The geometric mean for each group is given together
with one logarithmic standard error, and the number of mice used to obtain the
mean.
Significance was tested by the method of
" Student t
" test) applied to the
logarithms of the data.
In general, the drug-treated groups were compared with a control group
receiving only sheep red cells and eysteine though some experiments included a
control group receiving sheep red cells alone.
RESULTS
Effect of cysteine- upon PFC respome.-In several experiments, two sets of
controls were included, the one receiving sheep red cells and a series of saline
injections, the other sheep red cells and a series of eysteine injections. Where
mice were treated before the administration of antigen, there was no difference
between the results (Fig. 5 and 6). Where mice were treated after the adminis-
tration ofantigen (Fig. 1, M300; Fig. 3, M304; Fig. 7, M322), the response of the174 I. E. ADDISON AND M. C. BERENBAUM
cysteine group wassignificantly,though notgreatly, lowered in oneexperiment out
ofthree (M300).
Nitrogen mudard after antigen (day + 2).-Two experiments were performed,
each using a single dose of 2.5mg./kg. nitrogen mustard (Fig. 1). Cysteine
strongly inhibited the immunosuppressive activity of the drug.
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FIG. I.-Mice given sheep red cells on day 0 and, on day +2, either HN2, 2-6 mg./kg., with cysteine, HN22-5mg./kg. with saline, cysteine alone, or saline alone; number ofPFC/spleen measur6d on day +4. For each experiinental group is shown the geometric mean, ± I log. standaxd error, and the number of animals used to obtain the mean. Schedule for day +2: cysteine (Ig./kg.) or salinegivenjust beforedrug administration and thencysteine (0-5g./kg.) or saline 1, 4 and 5 hours later.
Cyclopho8phamide after antigen (day + 2): Fig. 2 illustrates one of two experi- ments in which eysteine significantly and markedly counteracted the immuno-
suppressive activity of cyclophosphamide at all doses (P < 0-05). Two single dose experime'nts were performed using a large dose ofdrug (300mg./kg., Fig. 3). The effect on immunosuppression was much less than that seen with smaller
doses (the reduction was 2-5-fold compared to 10- to 100-fold), and in only one of the two experiments (M304) was this reduction significant (P 0-01-0-02).
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Bmulphan before, antigen (-7 hr and day 1)
In an initialexperiment asingle dose of 90mg./kg. wasgiven 7 hours before the
antigen (Fig. 4). The effect ofeysteine on the degree ofimmunosuppression was
not significant.
In a secondexperiment a range ofdoses wasgiven I day beforeantigen (Fig. 5).
At a dose of 20mg./kg. there was no significant difference in PFC between mice
treated witheysteine and thosegivensaline, while at the twolarger doses there was
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FIG. 2.-Mice given sheep red cells on day 0 and, on day +2, either cyclophosphamide with
cysteine, cyclophosphamide with saline, or saline alone; nijmber of PFC/spleen measured
on day +4. For each experiinental group is shown the geometric mean, ± I log. standard
error, and the number of animals used to obtain the mean. Schedule for day +2: eysteine (I g./kg.) or saline given 0-5hour before drug and then cysteine (0-5g./kg.) or saline 2,
4 and 6 hours later.
0..O cyclophosphamide with cysteine
x x cyclophosphamide with saline.
a significant enhancement of the immunosuppressive activity of busulphan by eysteine (P < 0-05). To test this last observation, the experiment was repeated using the same and a second, fresh suspension ofbusulphan in arachis oil (Fig. 6). Again, an enhancement of immunosuppressive activity was seen (P 0-01-
0-002 for 90mg./kg. dose) but only with the fresh suspension. To summarize,
eysteine never inhibited the immunosuppressive effect ofbusulphan given before
the antigen; at times it significantly increased i't.Exp: M 304
Exp:M 295
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FIG. 3.-Mice given sheep red cells on day 0 and, on day +2, either cyclophosphamide
300 mg./kg. withcysteine,cyclophosphamide 300mg./kg. withsaline,cysteinealone, orsaline
alone; number ofPFC/spleen measured on day +4. For eachexperimental group is shown
the geometric mean ± 1 log. standard error and the number of animals used to obtain the
mean. Schedule for day +2: cysteine (1 g./kg.) or saline just before drug and cysteine
(0-5g./kg.) br saline 2 and 4 hours later.
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FiG. 4.-Mice given either busulphan (90mg./kg.) with saline, busulphan with cysteine, or
cysteine alone at -7 hours and sheep red cells on day 0: number ofPFC/spleen measured
on day +4. For each experiinental group is shown the geometric mean ± 1 log. standard
error, and the number of animaJs used to obtain the mean. Schedule: cysteine (1 g./kg.)
or saline just before injection of drug and cysteine (0-5g./kg.) or saline 2, 4, 5, 6 and 8
hours later.
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Bmulphan after antigen (day +2)
Two experiments were performed (Fig. 7). In the first experiment no signifi-
cant suppression was obtained with 90 mg./kg.; in contrast, the suppression
obtained with busulphan plus eysteine was significant (P 0-05-0-025).
In the second experiment, significant suppression was obtained with this dose
ofbusulphan and, to agreaterdegree, withbusulphanplus cysteine.
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Fie.. 5.-Mice given either busulphan with eysteine, busulphan with saline, eysteine alone, or
saline aJone on day -I and, on day 0, sheep red cells. PFC/spleen measured on day +4.
For each experimental group is shown the geometric mean ± I log. standard error, and the
number of animals used to obtain the mean. Schedule for day 1: cysteine (1 g./kg.)
or saline given just before drug injection and cysteine (0-5g./kg.) or saline 2, 4, 5, 6, 8 and 9
hours later.
0 0 busulphan with cysteine
x x busulphan with saline.
DISCUSSION
The toxicity of several alkvlating agents is reduced by eysteine, and Connors
(1966) summarized evidence thatprotection is due to a direct reaction between the
drug and cysteine, rather than any indirect mechanism. The immunosuppressive
effects of nitrogen mustard and cyclophosphamide are also reduced by adminis-
tration of eysteine. In the case of nitrogen mustard, this is probably due to a
direct reaction with cysteine before the alkylating agent is able to damage crucial
sites in cells mediating antibodyproduction. In the case ofcyclophosphamide, a
direct reaction is unlikely as this drug is largely un-ionized in vitro while, in vivo,
cyclophosphamide is oxidized in the liver to as yet unidentified metabolites
(Brock 1967; Brock and Hohorst, 1967; Friedman, 1967): it isprobably these that
are neutralized by eysteine.
The principal finding in the experiments reported here is that the immuno-
suppressive effects ofbusulphan were not reduced by massive and repeated doses178 I. E. ADDISON AND M. C. BERENBAUM
ofcysteine. ln fact, the reverse was usually true, eysteine significantlypotentia-
ting the effects of busulphan. This finding is in direct contrast to those with
other alkylating agents. However, it does not necessarily follow that busulphan
did not act as analkylatingagent intheseexperiments. Although 40-50molecules
ofcysteine were injected for every molecule ofbusulphan, theregimen ofcysteine
treatment adopted might have been inadequate for two reasons. In the first
place, cysteine may be eliminated much faster than busulphan. Fox, Craig and
Jackson (1960) found that, when labelled busulphan was administered to mice,
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FIG. 6.-(Twopreparations ofbusulphan inoil, P5 and P6 wereused.) Micegiven either busul-
phan (90mg./kg.) withcysteine, busulphan withsaline, cysteine alone or saline alone, onday 1. Sheep red cells given on day 0. PFC/spleen measured on day +4. For each
experimental group is shown the geometric mean ± I log. standard error and the number
of animals used to obtain the mean. Schedule for day 1: cysteine (I g./kg.) or saline at time ofdrug injection, then cysteine (0-5g./kg.) or saline 2, 4, 6 and 8 hours later.
O..o busulphan with cysteine
x x busulphan with saline.
60% oftheinjectedradioactivityappeared in the urine in the first 24 hours. This
is consistent with an in vivo half-life ofabout 18 hours (the half-Iffe ofbiologically activedrugmay, ofcourse,bemuchlessthanthis). Theinvivohalf-Iffeofcysteine,
on the otherhand, is about 20 minutes (Brincker, 1964) and thelevel ofprotein-free thiol in thespleenreturns to normal21 hours after aninjection of I g./kg. (Connors, 1966). Thisdifference in in vivo half-lives may account forthe failure of a number
of attempts to reduce the effects of busulphan with thiol compounds (Asano, Odell, McDonald and Upton, 1963; Ochoa and Hirschberg, 1967). Although, inthepresentexperiments,largedoses ofcysteine weregiven over aperiodspanning179 EFFECT OF CYSTEINE ON IMMUNOSUPPRESSIVE ACTIVITY
a considerableportion ofthe half-life ofbusulphan, it ispossible thatthe individual
pulses did not produce a high enough concentration at the crucial reaction site(s)
or did not do so for long enough.
In the secondplace, the reactionsundergonebybusulphan at its sites ofaction
in vivo will depend on the local concentrations and reactivities of various alkyla-
table groups including not only thiols but also water, nitrogenous bases and
ionized carboxylate (Ross, 1962). These local concentrations are unknown and
the reactivities ofthese groups at the relevant in vivo sites will depend in part on
the local molecularenvironment. Itispossible,therefore, that evenwheneysteine
ispresent at the crucial reaction site, busulphan may still reactpreferentially with
its normal target molecule(s).
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FiG. 7.-Mice given sheep red cells on day 0 and, on day +2, either busulphan (90mg./kg.) with eysteine, busulphan with saline, cysteine alone or saline alone. PFC/spleen measured
on day +4. For each experimental group is shown the geometric mean + I log. standard
error and the number ofanimals used to obtain the mean. Schedule for day +2: M302-
cysteine or salinegiven at time ofdruginjection andagain 2, 4 and 5-5 hours later. M322--
cysteine (I g./kg.) or saline given at tixne ofdrug injection and cysteine (0-5g./kg.) or saline
2, 4, 6 and 8 hours later.
For these reasons, negative results with cysteine are not conclusive evidence
against analkylating mode ofaction. However,theythrowdoubt onthehypothe- sis that busulphan exerts its biological effects particularly by reacting with thiols
in tissues. This hypothesis stems from the following considerations. Busulphan reacts with thiol groups in vivo as part of its major metabolic pathway (Roberts and Warwick, 1961): the complex formed by the attachment ofbusulphan to a
protein cysteinyl residue is degraded, the amino-acid sulphur being removed with
thebutylmoiety ofbusulphan to form atetrahydrothiophenecomplex, andleaving180 I. E. ADDISON AND M. C. BERENBAUM
behind an alanyl or seryl residue. The amino-acid sequence of the affected
protein thus is changed in a manner which might well interfere with its function.
Another possibility is that busulphan might combine with cysteinyl residues in
two peptide chains and so cross-link them (Roberts and Warwick, 1961). It
has been suggested that interference with the many enzyme systems containing
thiol groups might underlie the toxic effects of busulphan (Calabresi and Welch,
1965).
Part of the attraction of the thiol-combining hypothesis lies in the failure to
detect cross-linking of DNA with busulphan at biologically important doses.
This is believed to be the lesion initiating the biological effects of most other
alkylating agents (Ross, 1962; Alexander, 1969). Although busulphan is chemi-
cally a difunctional agent and although it reacts with DNA, cross-links are not
formed and the drug behaves as a monofunctional agent (Verly and Brakier,
1969). Some other explanation must therefore be sought for its effects. Doubt
has been thrown on dethiolation as the mechanism by which busulphan exerts
its effects because the in vivopool ofthiol-containing compounds would seem to be
too large to be affected significantly by doses of busulphan in the clinical range
(Boesen and Davis, 1969). Nevertheless, Harrap and Speed (1964) showed that
administration ofbusulphan in chronicmyeloid leukaemia led to a fall inleucocyte
glutathione, andthe dosesrequiredforimmunosuppressioninthe mouse(60 mg./kg.
or m6re) may be more effective in depletingparticular tissue thiols than the much
smaller doses (0-065 mg./kg./day) used in man. However, the findings ofHarrap
andSpeed (1964)might well have beensecondary to otherchanges in the leukaemic
cell population.
The experiments reported here also throw doubt on the thiol-depletion
hypothesis, for administration of excess exogenous thiol with busulphan, far
from ameliorating the immunos'uppressive effects of the drug, actually poten-
tiated them. It would be premature to speculate on the reasons for this effect,
but it raises the possibility that it is not busulphan itself that causes celldamage,
but a metabolite produced by the reaction between busulphan and thiols. One
such product (the major urinary metabolite, 3-hydroxy-tetrahydrothiophene-1, 1-dioxide) was found to be relatively non-toxic in the rat and rabbit by Roberts
and Warwick (1961), but these authors pointed out that cells might be imper- meable to this substance and that its production inside cells might be damaging (Roberts and Warwick, 1959).
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